Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyoto University And U.S. Izumi Bio Collaborate On iPS Research

This article was originally published in PharmAsia News

Executive Summary

Japan induced pluripotent stem cell research center Kyoto University signed a collaboration agreement with U.S. bioventure company iZumi Bio. The two will exchange information on creating human iPS cells using different methods and share analytic results on iPS cell's differentiation capabilities. Funded by major venture capital firms, iZumi obtained Bayer's iPS technology in February. Bayer had previously led Kyoto University in development and submitted the first patent application for iPS in Japan. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts